Balyasny Asset Management
JNCE

Balyasny Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Balyasny Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,177
Closed -$26K – 3387
2022
Q3 		$26K Buy
+11,177
New +$39.6K ﹤0.01% 2551
2018
Q3 		– Sell
-28,920
Closed -$222K – 2142
2018
Q2 		$222K Buy
+28,920
New +$417K ﹤0.01% 1615

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Balyasny Asset Management's JNCE Position: Q4 2022 in Review

Balyasny Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 11,177 shares — an estimated $26K sold.

Balyasny Asset Management first reported a position in JNCE in Q2 2018 and held it in 2 quarters. The position peaked at $222K in Q2 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

  • Balyasny Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 11,177 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $26K.
  • Balyasny Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Balyasny Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $222K in Q2 2018.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.